公开(公告)号：US11584777B2

公开(公告)日：2023-02-21

申请号：US16643355

申请日：2017-08-31

Applicant: GREEN CROSS CORPORATION

Inventor： Denis Feshin ,  Byung Hyun Park ,  Yong Won Shin

IPC: C07K1/22 ,  C07K1/18 ,  C07K1/36 ,  C12N9/16 ,  C07K1/34

Abstract: A method for purification of a sulfatase using metal chelating chromatography without using tags such as His-tag, etc. is disclosed. An embodiment provides a method for purifying a sulfatase including the steps of: (a) providing a sulfatase-containing solution comprising one or a plurality of impurities; (b) performing a first chromatographic separation of the sulfatase-containing solution using a metal affinity chromatography resin; (c) performing a second chromatographic separation using a cation exchange chromatography resin; and (d) performing a final chromatographic separation using an anion exchange chromatography resin, wherein the impurities are removed thereby.

公开(公告)号：US20230002379A1

公开(公告)日：2023-01-05

申请号：US17755843

申请日：2020-11-12

Applicant: YUHAN CORPORATION ,  GREEN CROSS CORPORATION

Inventor： Dong-Hoon KIM ,  Jae-Eun JOO ,  Eui-Chul LEE ,  Tae-Dong HAN ,  Seung-Yub SHIN ,  Sool-Ki KWON ,  Ji-Hye KIM

IPC: C07D471/08

Abstract: Provided are a compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and a use thereof, where the compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.

公开(公告)号：US20220162310A1

公开(公告)日：2022-05-26

申请号：US17602511

申请日：2020-05-22

Applicant: GREEN CROSS CORPORATION ,  MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Hye-Young PARK ,  Eun Jung SONG ,  Eun Hee LEE ,  Hye In YUM ,  Hye Mi NAM ,  Mun Kyung KIM ,  Jee Won LEE ,  Joong Hyuk SHEEN ,  Min Kyu HUR ,  So Jung LIM ,  Ok Jae LIM ,  Yang Mi LIM ,  Jong Hwa WON

IPC: C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/395

Abstract: The present invention relates to: an antibody to T cell Immunoreceptor with Ig and Tyrosine-Based Inhibitory Motif Domains (TIGIT), or an antigen-binding fragment thereof; a nucleic acid encoding same; a vector carrying the nucleic acid; a cell transformed with the vector; a method for producing the antibody or the antigen-binding fragment thereof; and a composition and a composition for combined administration, which comprise same and are for preventing or treating cancer.

公开(公告)号：US20220135679A1

公开(公告)日：2022-05-05

申请号：US17431218

申请日：2020-04-06

Applicant: GREEN CROSS CORPORATION

Inventor： Jae Chan PARK ,  Eun Jung SONG ,  So Jung LIM ,  Jae-Chul LEE ,  Hae Naem KWON ,  Su A LEE ,  Ok Jae LIM ,  Mun Kyung KIM ,  Hyun Jung CHO ,  Gil-Jung KIM ,  Jee Won LEE ,  Sung Keun KIM ,  Jong Wha WON ,  Shin A JANG

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30

Abstract: A bispecific anti-GPNMB/anti-CD3 antibody specifically binds to CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B) and uses thereof are disclosed. The bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB.

公开(公告)号：US20220112246A1

公开(公告)日：2022-04-14

申请号：US17417603

申请日：2020-01-14

Applicant: GREEN CROSS CORPORATION

Inventor： Jung-Hwan KIM ,  Woohyun KIM

IPC: C07K14/005 ,  A61K39/29 ,  C07K16/08

Abstract: A specific conformational epitope of a hepatitis B surface antigen and a hepatitis B neutralizing antibody binding thereto are disclosed. The epitope has a specific conformational structure. In addition, the conformational epitope does not contain the ‘a’ determinant that may generate an escape mutation upon administration of conventional vaccines or HBIg. Thus, an antibody capable of binding to the epitope is highly unlikely to allow the emergence of a vaccine escape mutation, which is caused by conventional vaccines, and as such, can retain a sustained effect. Therefore, such an antibody or a vaccine composition can find effective applications in the prevention and treatment of HBV, having great economic value.

公开(公告)号：US20210161111A1

公开(公告)日：2021-06-03

申请号：US16651200

申请日：2018-09-20

Applicant: GREEN CROSS CORPORATION ,  MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： So Ra KIM ,  Myung Eun JUNG ,  Min Jung KIM ,  Seung Hyun JO ,  Sung Ho HWANG ,  Hee Chun KWAK ,  Su Min LEE ,  Hyun Ja NAM

IPC: A01K67/027 ,  C12N15/113 ,  C12N9/22

Abstract: The present invention relates to a factor VIII or factor IX gene knockout rabbit, a method for preparing the same and a use thereof and, more particularly, to a transgenic rabbit whose factor VIII or factor IX gene has been knocked out through the CRISPR/Cas9 system, a method for preparing the same and a use thereof. According to the present invention, in the transgenic rabbit, whose factor VIII and/or factor IX gene has been knocked out, the functions of factor VIII and/or factor IX, which are proteins that perform critical functions for the development of hemophilia, are inhibited, such that the transgenic rabbit is useful for the development of hemophilia treatments.

公开(公告)号：US10561713B2

公开(公告)日：2020-02-18

申请号：US15738017

申请日：2016-07-04

Applicant: GREEN CROSS CORPORATION ,  MEDIGENEBIO CORPORATION

Inventor： Jin-Kyung Lee ,  Han-Yeul Byun ,  Myung-Eun Jung ,  Kyu-Hyun Lee

IPC: A61K38/46 ,  A61K9/00 ,  A61K38/16 ,  A61P3/00 ,  A61K47/02 ,  A61K47/18 ,  A61K47/26

Abstract: A Hunter syndrome therapeutic agent contains a first composition to be intravenously injected and a second composition to be subcutaneously injected. The agent can reduce the number of visits to the hospital by patients with Hunter syndrome to twice a month or less. It maintains a medicinal effect equivalent to or greater than that of a conventional once-a-week IV injection, increases drug-taking compliance of patients in comparison to conventional therapeutic agents and treatment methods, and enables enhanced patient welfare and convenience.

公开(公告)号：US20180346588A1

公开(公告)日：2018-12-06

申请号：US15762885

申请日：2016-09-23

Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH ,  GREEN CROSS CORPORATION

Inventor： Dong-Sik KIM ,  Eun Jung SONG ,  Mijung LEE ,  Eun-Hee LEE ,  Miyoung OH ,  Jae Chan PARK ,  Kisu KIM ,  Sujeong KIM ,  Hyung-Kwon LIM ,  Kyuhyun LEE ,  Jongwha WON ,  Soongyu CHOI ,  Young Seoub PARK

IPC: C07K16/30

CPC classification number: C07K16/30 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/92

Abstract: The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.

公开(公告)号：US20180303914A1

公开(公告)日：2018-10-25

申请号：US15738017

申请日：2016-07-04

Applicant: GREEN CROSS CORPORATION ,  MEDIGENEBIO CORPORATION

Inventor： Jin-Kyung LEE ,  Han-Yeul BYUN ,  Myung-Eun JUNG ,  Kyu-Hyun LEE

IPC: A61K38/46 ,  A61K9/00 ,  A61K47/02 ,  A61K47/18 ,  A61K47/26 ,  A61P3/00

Abstract: A Hunter syndrome therapeutic agent contains a first composition to be intravenously injected and a second composition to be subcutaneously injected. The agent can reduce the number of visits to the hospital by patients with Hunter syndrome to twice a month or less. It maintains a medicinal effect equivalent to or greater than that of a conventional once-a-week IV injection, increases drug-taking compliance of patients in comparison to conventional therapeutic agents and treatment methods, and enables enhanced patient welfare and convenience.

公开(公告)号：US09988372B2

公开(公告)日：2018-06-05

申请号：US15325521

申请日：2014-07-18

Applicant: GREEN CROSS CORPORATION ,  LEGOCHEM BIOSCIENCES,INC.

Inventor： Soongyu Choi ,  Jungsub Choi ,  So-Hyun Yoon ,  Yoo Hoon Kim ,  Jae Yeon Kim ,  Suk Ho Lee ,  Young Lag Cho ,  Ho Young Song ,  Dae Yon Lee ,  Sung Yoon Baek ,  Sang Eun Chae ,  Tae Kyo Park ,  Sung Ho Woo ,  Yong Zu Kim

IPC: C07D253/065 ,  C07D409/10 ,  C07D413/10 ,  A61K31/53 ,  C07D413/14

CPC classification number: C07D413/14 ,  A61K31/53 ,  A61P7/02 ,  A61P9/00 ,  A61P29/00 ,  C07B2200/13 ,  C07D253/065 ,  C07D409/10

Abstract: The present invention relates to a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism.